5% or 2% dextrose infusion, prevention of postoperative nausea and vomiting after laparoscopic surgery
Not Applicable
- Conditions
- Health Condition 1: K807- Calculus of gallbladder and bile duct without cholecystitis
- Registration Number
- CTRI/2022/12/047977
- Lead Sponsor
- Dr J Naveen kumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA grade I and II patients
Age between 18-65 years
Patients undergoing elective laparoscopic surgery under general anesthesia
Exclusion Criteria
Patients with physical status III or more
Patients with history of PONV, smoking, motion sickness, diabetes, hypertension, cardiac, renal or hepatic dysfunction, pregnant or menstruating patients, obesity (BMI > 30 kg/m2) and prolonged surgery ( >2 hours)
Subjects who could not use the verbal descriptive scale (VDS)
Patients receiving an antiemetic agent within 24 hours before surgery or cases where complications occurred during surgery.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method postoperative nausea and vomiting incidence and intensityTimepoint: postoperative nausea and vomiting incidence and intensity will be measured at PACU arrival at 30,60,90,120 and at 6,12,24hrs after surgery
- Secondary Outcome Measures
Name Time Method requirement of rescue antiemetic(single dose and repeated dose)Timepoint: time of oral acceptance of feed, blood sugar level will be measured using a point of device immediately before starting study fluid infusion, before induction, intraoperatively after induction followed by 60mins intervel and postoperatively at PACU arrival and at 2 and 6 hrs. postoperatively those who will develop nausea or vomiting will receive 0.1mg/kg iv ondansetron